Anti-SIRPa Monoclonal Antibody BI 765063 clinical trials
Also written BI 765063.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses Anti-SIRPa Monoclonal Antibody BI 765063 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Boehringer Ingelheim (4) · OSE Immunotherapeutics (1)
Often tested with
Tested in the same studies.
Ezabenlimab (3) · Anti-SIRPa Monoclonal Antibody BI 770371 (1)
Studies
Open first, then newest update. How each study uses Anti-SIRPa Monoclonal Antibody BI 765063 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingPhase 1Boehringer IngelheimNCT05068102Written as BI 765063How we know
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver CancerCompletedPhase 1Boehringer IngelheimNCT05249426Written as BI 765063How we know
- A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid TumoursCompletedPhase 1OSE ImmunotherapeuticsNCT03990233Written as BI 765063How we know
- A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in SurgeryTerminatedPhase 1Boehringer IngelheimNCT05446129Written as BI 765063How we know
- A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)CompletedPhase 1Boehringer IngelheimNCT04653142Written as BI 765063How we know